Department of Cardiology, Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Basic Medicine College, Shandong First Medical University, Jinan, Shandong, 250062, China.
Hellenic J Cardiol. 2021 Jul-Aug;62(4):265-269. doi: 10.1016/j.hjc.2020.12.004. Epub 2020 Dec 8.
Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2, is currently in a pandemic outbreak and has become a global health issue. In addition to the primarily involvement of the respiratory system, myocarditis is considered an important and fatal lesion in patients with COVID-19. However, effective therapeutic methods are currently lacking. The cholinergic anti-inflammatory pathway (CAP) has been demonstrated to suppress pro-inflammatory cytokine production and control inflammation in sepsis and other medical conditions. Therefore, the CAP may be a potential and effective therapeutic method for COVID-19-related myocarditis. This article reviews the relationship between COVID-19-related myocarditis and the CAP and discusses the CAP as a potential therapeutic modality in the treatment of COVID-19-related myocarditis.
新型冠状病毒病（COVID-19）由严重急性呼吸综合征冠状病毒-2 引起，目前正处于大流行爆发阶段，已成为全球性健康问题。除了主要涉及呼吸系统外，心肌炎被认为是 COVID-19 患者的重要致命病变。然而，目前缺乏有效的治疗方法。胆碱能抗炎途径（CAP）已被证明可抑制败血症和其他疾病中的促炎细胞因子产生并控制炎症。因此，CAP 可能是 COVID-19 相关心肌炎的一种潜在有效治疗方法。本文综述了 COVID-19 相关心肌炎与 CAP 的关系，并讨论了 CAP 作为 COVID-19 相关心肌炎治疗的一种潜在治疗方式。
